They're discussing a link between eating protein and stimulating your body’s GLP-1 levels. But is there something to this, or ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

Cedars-Sinai experts believe the study's findings can play a crucial role in developing healthcare policies that promote ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

THURSDAY, Oct. 24, 2024 (HealthDay News) -- Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and ...

Semaglutide falls under a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1s, which mimic the ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy.

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to ...